|Bid||75.66 x 200|
|Ask||77.50 x 100|
|Day's range||73.17 - 76.59|
|52-week range||20.12 - 134.00|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||136.00|
AnaptysBio dipped Tuesday despite trial results showing its peanut-allergy drug improved symptoms in nearly half of adult patients tested.
The Soros Fund Management opened up smallish positions in the mid-cap biotechs DexCom and AnaptysBio in the most recent quarter.
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.